Core Insights - 博瑞医药 has made significant progress in clinical trials for multiple core innovative drugs, showcasing its strong research and development capabilities [1][2][3] Group 1: Key Products - BGM0504, a core candidate drug, shows potential for treating metabolic diseases by activating GIP and GLP-1 pathways, aiding in blood sugar control, weight loss, and treatment of non-alcoholic fatty liver disease (NASH) [1] - BGM0504 injection is advancing in clinical trials across multiple regions, including China and Indonesia, with positive results in phase III studies [1] - The oral formulation of BGM0504 has received IND approval in China and the U.S., with the first subject dosed, indicating steady progress in global development and future commercialization [1] - BGM1812, another core product, is a novel long-acting Amylin analog designed to promote weight loss through multiple mechanisms, including activating brain satiety pathways [2] - BGM1812 has received clinical trial approval in both China and the U.S., with the first clinical enrollment successfully completed, positioning 博瑞医药 to capture a key advantage in the global weight loss drug market [2] - The combination formulation BGM2102, which integrates the advantages of dual-target agonists and Amylin analogs, aims to address the treatment needs of severely obese and precision weight loss patients [2] Group 2: Research and Development - 博瑞医药 is advancing other research projects, including peptide-based hypoglycemic drugs, anti-tumor drugs, and innovative developments in immune diseases, all progressing according to research plans [2] - The company is also deepening its technical platform for complex formulations, such as inhalation drugs, laying a foundation for future product pipeline expansion [2] - 博瑞医药 adheres to compliance in research and development, ensuring that all clinical trials follow international standards and relevant laws, with a commitment to timely and accurate disclosure of project progress [3]

创新药子公司将作为公司布局创新药领域的核心载体，围绕存在重大未被满足临床需求的疾病领域进行 前瞻性布局，将重点关注免疫抗肿瘤、自身免疫性疾病等方向，并视研发进展及市场环境变化，适时拓 展至心血管、内分泌等其他具有发展潜力的领域。创新药子公司将借鉴行业成熟运营模式，通过自主研 发、产品引进及收购、合资共建、股权投资等多维方式推进创新药管线建设，构建研发、转化、产业化 全链条闭环运营体系，提升公司在创新药领域的专业化投资与市场化运营能力。 格隆汇1月26日丨成大生物(688739.SH)公布，为落实公司疫苗与创新药双轮驱动的长期发展战略，把握 创新生物药领域的发展机遇，公司拟以自有资金10亿元设立创新药子公司，持有其100%股权。为提高 资金使用效率，注册资本将根据业务拓展节奏及研发项目进度分期注入，实现资金投入与项目需求的动 态匹配。该创新药子公司将专注于创新药研发、优质项目引进与并购、核心团队搭建及专业化运营体系 建设，助力公司打造第二增长曲线。 ...

北京商报讯(记者王寅浩宋雨盈)1月26日，恒瑞医药（600276）发布公告称，公司收到国家药品监督管 理局核准签发关于SHR-1049注射液的《药物临床试验批准通知书》，将于近期开展临床试验。根据公 告，SHR-1049注射液是创新型抗肿瘤药物，拟用于治疗晚期实体瘤，目前国内外尚无同类药物获批上 市。 ...

格隆汇1月26日丨辽宁成大(600739.SH)公布，成大生物为推进发展战略，积极把握创新生物药领域的发 展机遇，拟以自有资金10亿元投资设立全资子公司成大生物创新制药有限公司（暂定名）。成大生物持 有该子公司100%股权，出资资金将专项用于创新药研发、优质项目引进与并购、核心团队搭建及专业 化运营体系建设，为其打造第二增长曲线。 创新药子公司将作为成大生物布局创新药领域的核心载体，围绕存在重大未被满足临床需求的疾病领域 进行前瞻性布局，将重点关注免疫抗肿瘤、自身免疫性疾病等方向，并视研发进展及市场环境变化，适 时拓展至心血管、内分泌等其他具有发展潜力的领域。创新药子公司将借鉴行业成熟运营模式，通过自 主研发、产品引进及收购、合资共建、股权投资等多维方式推进创新药管线建设，构建研发、转化、产 业化全链条闭环运营体系，提升公司在创新药领域的专业化投资与市场化运营能力。 ...

格隆汇1月26日丨恒瑞医药(01276.HK)发布公告，近日，公司收到国家药监局核准签发关于SHR-1049注 射液的《药物临床试验批准通知书》，将于近期开展临床试验。SHR-1049注射液是公司自主研发的创 新型抗肿瘤药物，拟用于治疗晚期实体瘤。经查询，目前国内外尚无同类药物获批上市。 ...

每经AI快讯，1月26日，恒瑞医药（600276）(600276.SH)公告称，公司收到国家药监局核准签发关于 SHR-1049注射液的《药物临床试验批准通知书》，同意开展单药在晚期实体瘤中的临床试验。SHR- 1049注射液是公司自主研发的创新型抗肿瘤药物，拟用于治疗晚期实体瘤。经查询，目前国内外尚无同 类药物获批上市。 ...

格隆汇1月26日｜恒瑞医药公告，公司收到国家药品监督管理局核准签发关于SHR-1049注射液的《药物 临床试验批准通知书》，将于近期开展临床试验。SHR-1049注射液是公司自主研发的创新型抗肿瘤药 物，拟用于治疗晚期实体瘤。经查询，目前国内外尚无同类药物获批上市。截至目前，SHR-1049注射 液相关项目累计研发投入约为2,600万元(未经审计)。 ...

Core Viewpoint - Jiangsu Lianhuan Pharmaceutical Co., Ltd. is expected to report a net loss of between 83 million to 99 million yuan for the year 2025, marking its first annual loss since going public, with a year-on-year decline of 217.63% to 198.62% [2][3] Financial Performance - In 2024, the company experienced a slight decline in revenue, achieving 2.16 billion yuan, a decrease of 0.63% year-on-year; net profit attributable to shareholders fell by 37.66% to 84.16 million yuan, while the net profit after deducting non-recurring items dropped by 56.89% to 49.87 million yuan [3] - The projected net loss for 2025 represents a decrease of 166.7 million to 183 million yuan compared to the previous year, with a decline exceeding 200%; the net profit after deducting non-recurring items is expected to be a loss of 32.5 million to 39 million yuan, down by 82.37 million to 88.87 million yuan [3] Regulatory Impact - The company faced a significant antitrust fine of 61.04 million yuan, which directly impacted its net profit; this fine accounted for 72.53% of the audited net profit for 2024 and 2.83% of the annual revenue, leading to a direct reduction of 61.04 million yuan in the projected net profit for 2025 [4] Operational Challenges - The company is under pressure from industry policy adjustments, high R&D costs, and restricted financing channels, which have contributed to its declining performance; the core product's gross margin is under pressure due to national drug procurement policies and increased international market competition [5] - The price of dexamethasone phosphate sodium, a key raw material, has plummeted to between 0.23 yuan and 0.57 yuan per unit post-antitrust penalty, significantly lower than the maximum price of 98.76 yuan during the period of monopoly, compressing the profitability of related businesses [5] R&D and Financing - The company has been increasing its R&D investment significantly, with expenses rising from 66 million yuan in 2021 to 155 million yuan in 2024, averaging over 30% annual growth; however, this sustained investment continues to pressure profit margins [5] - The company has faced challenges in financing, with two failed fundraising attempts in 2024 totaling 7.35 million yuan, which were terminated due to "market environment changes and the company's actual operating conditions"; it has since sought debt financing, applying for a 240 million yuan R&D loan [6] Future Outlook - The company is exploring how to address the profit gap created by the antitrust fine and whether the 240 million yuan R&D loan will be successfully secured; there are concerns regarding its cash flow situation and how it will restructure its core profit segments to achieve profitability [7]

Summary of Baicheng Pharmaceutical Conference Call Company Overview - **Company**: Baicheng Pharmaceutical - **Date**: January 25, 2026 Key Points Industry and Company Developments - Baicheng Pharmaceutical is committed to innovation and has received multiple clinical approvals for first and second-class new drugs, with expectations for significant performance contributions in the next 2-3 years [2][3] - The company has established a strategic partnership with Italian company Diling to accelerate European GMP certification and overseas CMO/CDMO order acquisition, enjoying priority rights for high-value products in Greater China [2][4] - The generic drug market is expected to see a price recovery in 2026 after a low in Q1 2025, with increased approval standards leading to a concentration in sales [2][6] Financial Performance and Projections - Baicheng Pharmaceutical's sales business is recovering from a low point in Q1 2025, with both demand and pricing showing positive trends [3] - The company has received over 190 approvals for third and fourth-class generic drugs, maintaining stable core operations [3] - Saimo, a subsidiary, won bids for 12 products in the 11th batch of centralized procurement, with substantial order volumes expected to enhance capacity utilization and profitability [2][7] - Sanmu Company is projected to see significant revenue and profit growth in 2026, with overseas market expansion further increasing capacity utilization [2][8] Innovation and Clinical Progress - Baicheng Pharmaceutical's innovation drug segment focuses on CNS, autoimmune diseases, and oncology, with several projects entering clinical stages [2][10] - The 0,118 project for narcolepsy is expected to complete its Phase II trial and report in the first half of the year [2][11] - The company plans to continue investing in its pipeline, with specific projects advancing based on customer interest [11] Strategic Collaborations - The partnership with Diling includes registering high-quality products for European GMP certification and prioritizing clinical submissions in Europe for products requiring extensive clinical trials [4][5] - The financial impact of the collaboration is expected to be minimal in 2026, with commercial orders anticipated post-2027 approval of innovative oral formulations [9] Future Outlook - The chairman of Baicheng Pharmaceutical emphasizes a strong commitment to developing generic drug R&D, CRO business, and expanding Saimo's operations while increasing investment in innovative drug development [12] - The company aims to leverage collaborations with domestic and international clients to launch new products and prioritize strategic international business development, including raw material and formulation exports [12]

Core Viewpoint - Dize Pharmaceutical is seeking to list on the Hong Kong Stock Exchange to alleviate its ongoing financial pressures despite recent revenue growth and reduced losses from its core products [1][4]. Financial Performance - In 2024, Dize Pharmaceutical's revenue is projected to be 360 million RMB, with losses narrowing to 940 million RMB; in the first three quarters of 2025, revenue is expected to rise to 586 million RMB, a year-on-year increase of over 73%, while losses are expected to decrease to 583 million RMB [1][4]. - The company has accumulated losses exceeding 4.567 billion RMB since its establishment in 2017, with R&D expenses totaling 3.853 billion RMB from 2018 to 2024 [6]. Product Development - Revenue growth is primarily driven by two core products: Shuwozhe® (Shuwotini tablets) and Gaoruizhe® (Golisitin capsules), which were launched in August 2023 and June 2024, respectively, and are expected to be included in the national medical insurance directory by the end of 2024 [4][6]. - The flagship product, Shuwozhe®, is projected to contribute revenues of 311 million RMB in 2024 and 422 million RMB in the first three quarters of 2025 [4]. Funding and Capital Strategy - Dize Pharmaceutical has relied heavily on capital markets for funding, raising approximately 2.103 billion RMB through its IPO on the STAR Market in 2021 and planning to raise about 1.796 billion RMB through a private placement in 2025 [6]. - The company aims to use the proceeds from its Hong Kong listing to enhance its R&D efforts and support the clinical development of its products [7]. Market Positioning - The decision to list in Hong Kong is part of Dize Pharmaceutical's strategy to deepen its global presence and enhance its international brand image, while also addressing the structural challenges of "increasing revenue without increasing cash" [4][7].